Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 15/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177649 | 0.84 | KMT2A (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2181102 | 0.82 | PDE4A (0.32) | — | |
| SCHEMBL1232020 | 0.81 | CYP3A4 (0.35) | ABCB1 | |
| SCHEMBL2180329 | 0.81 | CHRNB2 (0.34) | ABCB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16586412 | 0.78 | MAPT (0.36) | — | |
| SCHEMBL20568239 | 0.78 | PDE4B (0.43) | — | |
| SCHEMBL1233222 | 0.75 | CYP3A4 (0.35) | ABCB1 | |
| SCHEMBL12484843 | 0.71 | PDE4B (0.53) | — | |
| SCHEMBL2178410 | 0.70 | CHRNB2 (0.37) | ABCB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19513344 | 0.69 | CXCR2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289000-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8470803-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2348863-A1 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110166103-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010027975-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166103-A1 | BORON-CONTAINING SMALL MOLECULES | NFKBIA, BCL6B, TNF | ABCB1 390/4885USP30 2916/4885CHRNB2 3527/4885 |
| US-20130289000-A1 | BORON-CONTAINING SMALL MOLECULES | NFKBIA, BCL6B, TNF | ABCB1 390/4885USP30 2916/4885CHRNB2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.